Pisani Silvia, Tufail Shafia, Rosalia Mariella, Dorati Rossella, Genta Ida, Chiesa Enrica, Conti Bice
Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Department of Drug Sciences, IUSS Scuola Universitaria Superiore Pavia, 27100 Pavia, Italy.
J Funct Biomater. 2024 Jul 15;15(7):194. doi: 10.3390/jfb15070194.
The fight against infectious disease has remained an ever-evolving challenge in the landscape of healthcare. The ability of pathogens to develop resistance against conventional drug treatments has decreased the effectiveness of therapeutic interventions, and antibiotic resistance is recognized as one of the main challenges of our time. The goal of this systematic review paper is to provide insight into the research papers published on innovative nanosized drug delivery systems (DDSs) based on gentamycin and vancomycin and to discuss the opportunity of their repurposing through nano DDS formulations. These two antibiotics are selected because (i) gentamicin is the first-line drug used to treat suspected or confirmed infections caused by Gram-negative bacterial infections and (ii) vancomycin is used to treat serious Gram-positive bacterial infections. Moreover, both antibiotics have severe adverse effects, and one of the purposes of their formulation as nanosized DDSs is to overcome them. The review paper includes an introduction focusing on the challenges of infectious diseases and traditional therapeutic treatments, a brief description of the chemical and pharmacological properties of gentamicin and vancomycin, case studies from the literature on innovative nanosized DDSs as carriers of the two antibiotic drugs, and a discussion of the results found in the literature.
在医疗保健领域,抗击传染病一直是一项不断演变的挑战。病原体对传统药物治疗产生耐药性的能力降低了治疗干预的效果,抗生素耐药性被认为是我们这个时代的主要挑战之一。本系统综述论文的目的是深入了解基于庆大霉素和万古霉素的创新纳米药物递送系统(DDS)的研究论文,并讨论通过纳米DDS制剂对其进行重新利用的机会。选择这两种抗生素是因为:(i)庆大霉素是用于治疗由革兰氏阴性菌感染引起的疑似或确诊感染的一线药物;(ii)万古霉素用于治疗严重的革兰氏阳性菌感染。此外,这两种抗生素都有严重的副作用,将它们制成纳米DDS的目的之一就是克服这些副作用。该综述论文包括一个聚焦于传染病和传统治疗方法挑战的引言、对庆大霉素和万古霉素化学及药理特性的简要描述、来自文献中关于将创新纳米DDS作为这两种抗生素药物载体的案例研究,以及对文献中研究结果的讨论。